Last reviewed · How we verify
Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT is a Small molecule drug developed by Maastricht University Medical Center. It is currently FDA-approved.
At a glance
| Generic name | Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT |
|---|---|
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT CI brief — competitive landscape report
- Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI
Frequently asked questions about Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
What is Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT?
Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT is a Small molecule drug developed by Maastricht University Medical Center.
Who makes Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT?
Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT is developed and marketed by Maastricht University Medical Center (see full Maastricht University Medical Center pipeline at /company/maastricht-university-medical-center).
What development phase is Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT in?
Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT is FDA-approved (marketed).